Hence our efforts to demonstrate the feasibility of targeting IL1RAP-expressing AML cells with antibody–drug conjugates, a mechanism solely dependent on IL1RAP expression and not expected to be influenced by FLT3 status. This evidence concerns the gene FLT3 and acute myeloid leukemia.